timothy sykes logo
BIVI Stock Jumps As SUNRISE-PD Data Fuels Parkinson’s Hopes Thumbnail
G Google News

BIVI Stock Jumps As SUNRISE-PD Data Fuels Parkinson’s Hopes

BRYCE TUOHEY•UPDATED AUG. 13, 2026, 7:47 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

BioVie Inc. shares surged as positive clinical-trial news boosted investor optimism, and stocks have been trading up by 14.13 percent.

Key Takeaways

  • Phase 2 SUNRISE-PD trial in early Parkinson’s met its primary endpoint, with bezisterim improving biomarkers tied to inflammation and neurodegeneration and delivering better motor and non-motor outcomes vs placebo.
  • Topline SUNRISE-PD data showed statistically significant gains on standard Parkinson’s scales MDS‑UPDRS I–III and composite EPNIC‑15, backed by strong biomarker signals and a placebo-like safety profile.
  • Trial strength supports moving bezisterim into a potentially pivotal Phase 3 program and expands BioVie’s neurodegenerative pipeline potential.
  • A new Schedule 13G filing revealed a fresh or increased beneficial ownership stake in BioVie Inc. (BIVI), signaling a passive but notable shareholder stepping in.

Candlestick Chart

Live Update At 07:47:20 EDT: On Thursday, August 13, 2026 BioVie Inc. stock [NASDAQ: BIVI] is trending up by 14.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIVI is trading like a classic biotech battleground name. The daily chart shows BioVie Inc. stuck around the $1.30–$1.45 range for weeks, then ripping on the SUNRISE-PD headlines. On 2026/08/12, BIVI spiked from a $1.35 open to a $3.79 high before fading to close at $1.56. That kind of intraday range screams momentum trading, not slow money.

Short term, BIVI has been closing mostly between $1.10 and $2.04 across recent sessions, a wide band that tells traders one thing: volatility is the edge here. Intraday, the 5‑minute tape shows BioVie opening around $1.83 at 04:00, flushing to the $1.58 area, then grinding back into the high $1.70s to low $1.80s. Choppy, but liquid enough for active day trading.

More Breaking News

On the fundamentals, BioVie Inc. is still a development-stage biotech. The latest quarterly data show a net loss of about $5.3M and operating cash outflow of roughly $7.4M. Cash on hand sits near $13.1M, with a hefty current ratio of 10 and very low debt, so BIVI is not a balance‑sheet disaster. Still, returns on equity and assets are deep in the red, reminding traders this is a clinical trial story, not a cash cow.

Why Traders Are Watching BIVI Right Now

BIVI just delivered what traders look for in small-cap biotech: a clear, clean clinical catalyst. BioVie Inc. reported positive Phase 2 SUNRISE-PD data for bezisterim in early-stage Parkinson’s disease, and this is not a “soft” win. The trial met its primary endpoint and showed improvements in both inflammatory and neurodegeneration biomarkers. That matters because it ties the clinical benefit to biology, not just survey scores.

Traders drilling into the details will like that BIVI saw statistically significant gains vs placebo on MDS‑UPDRS I–III, the standard scales that track motor and non-motor Parkinson’s symptoms. The composite EPNIC‑15 score also improved. When a small-cap like BioVie Inc. posts multiple significant endpoints plus strong proteomic biomarker signals, the market often reassesses the probability of success in Phase 3.

Equally important for BIVI, bezisterim showed a placebo-like safety profile. Parkinson’s patients are typically older and fragile; safety scares kill these stories fast. The fact that BioVie Inc. can talk about efficacy, biomarkers, and tolerability in the same breath is a de‑risking moment for the pipeline.

The company is already framing these SUNRISE-PD results as support for advancing bezisterim into a potentially pivotal Phase 3 trial. That sets up the classic biotech trading cycle: run‑ups into Phase 3 design updates, partnership chatter, or regulatory feedback. Layer on the Schedule 13G: a new or enlarged passive owner stepping into BIVI after this data adds another signal that someone with size is taking the story seriously. Traders don’t treat that as a guarantee, but they do pay attention.

Conclusion

For active traders, BIVI is now a textbook news‑driven biotech. BioVie Inc. has a Phase 2 win in early Parkinson’s, anchored by statistically significant MDS‑UPDRS and EPNIC‑15 improvements, backed by anti‑inflammatory and neurodegeneration biomarker changes and a placebo‑like safety profile. That combination gives bezisterim real credibility as it heads toward a potential Phase 3 and lifts the overall neurodegeneration narrative around BioVie.

At the same time, the financials remind everyone that BIVI is burning cash, generating no meaningful revenue, and living on its balance sheet and capital markets access. The strong current ratio and modest debt buy BioVie Inc. time, but traders should assume future raises are always on the table when clinical programs move forward. The new 13G holder adds a supportive backdrop, yet it remains a sentiment flag, not a safety net.

For short-term players, the tape is the tell. Wide daily ranges, sharp intraday reversals, and volume spikes around headlines make BIVI a pure trading vehicle right now. Longer-term swing traders will focus on how BioVie Inc. communicates its Phase 3 strategy and whether more institutions appear on the shareholder list.

Tim Sykes likes to say, “Volatility is opportunity, but only for prepared traders.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. BIVI embodies that idea. The SUNRISE-PD data turned BioVie from a quiet biotech into a live catalyst play, and traders who study the news, the chart, and the risk can treat it as an educational case study in how clinical headlines reshape a small-cap stock. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”